Somos una red de profesionales sin ánimo de lucro dedicada a fomentar y divulgar los avances científicos y la enseñanza de la neuro-oncología siguiendo el más alto nivel científico.

+57 312 864 15 72
Cra 25 # 3 - 45 | El Poblado, Medellín

Entradas recientes

Cra 25 # 3 - 45

El Poblado, Medellín

+57 312 864 15 72


Lo que usted debe saber

RedLANO Red Latinoamericana de Neuro-oncología  >  Lo que usted debe saber

Referencias Recomendadas 2011
La Red Latino Americana de Neuro-Oncología, al igual que otras sociedades afines, invita a evaluar la siguiente serie de manuscritos seleccionados de la producción editorial del año 2011.

Genesis tumoral
Bettegowda, C. Mutations in CIC and FUBP1 contribute to human oligodendroglioma. Science. 2011 Sep 9;333(6048):1453-5.
Schwartzentruber, J. et al. Driver mutations in histone H3.3 and chromatin remodelling genes in pediatric glioblastoma. Nature. 2012 Jan 29.
Schindler, G. et. al. Analysis of BRAF V600E mutation in 1,320 nervous system tumors reveals high mutation frequencies in pleomorphic xanthoastrocytoma, ganglioglioma and extra-cerebellar pilocytic astrocytoma. Acta Neurpatholo 2011 Mar;121(3):397-405.

Paugh, B. S. et. al. Genome-wide analyses identify recurrent amplifications of receptor tyrosine kinases and cell-cycle regulatory genes in diffuse intrinsic pontine glioma. J Clin Oncol2011 Oct 20;29(30):3999-4006.

Metastasis cerebrales

Kocher, M. et. al. Adjuvant whole-brain radiotherapy versus observation after radiosurgery or surgical resection of one to three cerebral metastases: results of the EORTC 22952-26001 study. J Clin Oncol. 2011 Jan 10;29(2):134-41.

Rochet, N. M. et. al. Vemurafenib for melanoma metastases to the brain. N Engl J Med. 2011 Dec 22;365(25):2439-41.
Tsao, M. et. al. A meta-analysis evaluating stereotactic radiosurgery, whole-brain radiotherapy, or both for patients presenting with a limited number of brain metastases. Cancer. 2011 Sep 1.

Gliomas de bajo grado

Daniels, T.B. et. al. Validation of EORTC prognostic factors for adults with low-grade glioma: a report using intergroup 86-72-51. Int J Radiat Oncol Biol Phys. 2011 Sep 1;81(1):218-24.

Aaronson, N. K. et. al. Compromised health-related quality of life in patients with low-grade glioma. J Clin Oncol. 2011 Nov 20;29(33):4430-5.

Van den Bent, M. J. et. al. Response assessment in neuro-oncology (a report of the RANO group): assessment of outcome in trials of diffuse low-grade gliomas. Lancet Oncol. 2011 Jun;12(6):583-93.


Sumazin, P. et. al. An extensive microRNA-mediated network of RNA-RNA interactions regulates established oncogenic pathways in glioblastoma. Cell. 2011 Oct 14;147(2):370-81.

Perez-Larraya, J. G. et. al. Temozolomide in Elderly Patients With Newly Diagnosed Glioblastoma and Poor Performance Status: An ANOCEF Phase II Trial. J Clin Oncol. 2011. Aug 1;29(22):3050-5.
Wheeler, C. J. and Black, K. L. Vaccines for glioblastoma and high-grade glioma. Expert Rev Vaccines. 2011 Jun;10(6):875-86.

Michelakis, E. D. et. al. Metabolic Modulation of Glioblastomawith Dichloroacetate. Sci Transl Med. 2010 May 12;2(31):31ra34.
Lai, A. et. al. Phase II study of bevacizumab plus temozolomide during and after radiation therapy for patients with newly diagnosed glioblastoma multiforme. J Clin Oncol. 2011 Jan 10;29(2):142-8.

Linfoma primario del sistema nervioso central

Fritsch, K. et. al, Immunochemotherapy with rituximab, methotrexate, procarbazine, and lomustine for primary CNS lymphoma (PCNSL) in the elderly. Ann Oncol. 2011 Sep;22(9):2080-5.

Abla, O. et. al. Primary CNS lymphoma in children and adolescents: a descriptive analysis from the International Primary CNS Lymphoma Collaborative Group (IPCG). Clin Cancer Res. 2011 Jan 15;17(2):346-52.

Baraniskin, A. et. al. Identification of microRNAs in the cerebrospinal fluid as marker for primary diffuse large B-cell lymphoma of the central nervous system. Blood. 2011 Mar 17;117(11):3140-6.

Meduloblastoma y otras neoplasias de origen neural

Parsons, D. W. et. al. The genetic landscape of the childhood cancer medulloblastoma. Science. 2011 Jan 28;331(6016):435-9.

Cho, Y. J. et. al. Integrative genomic analysis of medulloblastoma identifies a molecular subgroup that drives poor clinical outcome. J Clin Oncol. 2011 Apr 10;29(11):1424-30.

Remke, M. et. al. Adult Medulloblastoma Comprises Three Major Molecular Variants. J Clin Oncol. 2011

Neuro-oncología pediátrica
Taylor, M. D. et. al. Molecular subgroups of medulloblastoma: the current consensus. Acta Neuropathol 2011 Dec 2.
Hawkins, C. et. al. Viruses and human brain tumors: cytomegalovirus enters the fray. J Clin. Investigation 2011 Oct 3;121(10):3831-3.
Barawno, N. et. al. Detection of human cytomegalovirus in medulloblastomas reveals a potential therapeutic target. J Clinical Investgation 2011 Oct 3;121(10):4043-55
Metcalfe, C. and de Sauvage, F. J. Hedgehog fights back: mechanisms of acquired resistance against Smoothened antagonists. Cancer Res 2011 Aug 1;71(15):5057-61
von Bueren, A. O. et. al. Treatment of young children with localized medulloblastoma by chemotherapy alone: results of the prospective, multicenter trial HIT 2000 confirming the prognostic impact of histology. Neuro Onco 2011 Jun;13(6):669-79.
Rodriguez, E. F. et. al. PI3K/AKT pathway alterations are associated with clinically aggressive and histologically anaplastic subsets of pilocytic astrocytoma. Acta Neuropathol 2011 Mar;121(3):407-20.

Ellison, D. W. et. al. Histopathological grading of pediatric ependymoma: reproducibility and clinical relevance in European trial cohorts. J Negat Results Biomed. 2011 May 31;10:7.


Chang, E. F. et. al. Functional mapping-guided resection of low-grade gliomas in eloquent areas of the brain: improvement of long-term survival. J Neurosurg. 2011 Mar;114(3):566-73.

Schucht, P. and Duffau, H. New-onset epilepsy: considerations for initial and follow-up MRI to detect brain tumor. Expert Rev Neurother. 2011 Aug;11(8):1107-10.

Cahill, K. S. and Claus, E. B. Treatment and survival of patients with nonmalignant intracranial meningioma: results from the Surveillance, Epidemiology, and End Results Program of the National Cancer Institute. J Neurosurg. 2011 Aug;115(2):259-67.

Yordanova, Y. N. et. al. Awake surgery for WHO Grade II gliomas within “noneloquent” areas in the left dominant hemisphere: toward a “supratotal” resection. J Neurosurg. 2011 Aug;115(2):232-9.

Senft, C. et. al. Intraoperative MRI guidance and extent of resection in glioma surgery: a randomised, controlled trial. Lancet Oncol2011; 12: 997–1003

Cuidado paliativo y medidas de soporte

Fleming, J. and O’Gorman, A.  High grade brain tumours: managing symptoms from diagnosis to terminal phase. European Journal of Palliative Care. Jan/Feb 2011, Vol 18 No1, pp 6-9.

Gehring, K. et. al. A description of a cognitive rehabilitation programme evaluated in brain tumour patients with mild to moderate cognitive deficits. Clin Rehabil. 2011 Aug;25(8):675-92.

McCartney, A. et. al. Exploring access to rehabilitation services from allied health professionals for patients with primary high grade brain tumours. Palliat Med. 2011 Dec;25(8):788-96.

Ownsworth, T. et. al. Making sense of a brain tumour : A qualitative investigation of personal and social processes of adjustment. Neuropsychological Rehabilitation. Vol 21, Issue 1. 2011, pp 117-137

Rayner, L. et. al. The development of evidence-based European guidelines on the management of depression in palliative cancer care. Eur J Cancer. 2011 Mar;47(5):702-12.

Rooney, A.G. et. al. Frequency, clinical associations, and longitudinal course of major depressive disorder in adults with cerebral glioma. J Clin Oncol. 2011 Nov 10;29(32):4307-12.

Ryan, R. et. al. Corticosteroid-use in primary and secondary brain tumour patients: a review. J Neurooncol. 2011 Oct 5.

Vargo, M. Brain tumor rehabilitation. Am J Phys Med Rehabil. 2011 May;90(5Suppl 1):S50-62. Review.

Neuroradiología y tumores del sistema nervioso
Choi, C. et al. 2-hydroxyglutarate detection by magnetic resonance spectroscopy in subjects with IDH-mutated gliomas. Nat Med. 2012 Jan 26.

Bähr, O. et. al. Bevacizumab-induced tumor calcifications as a surrogate marker of outcome in patients with glioblastoma. Neuro Oncol. 2011 Sep;13(9):1020-9.

Ellingson, B. M. et. al. Graded functional diffusion map-defined characteristics of apparent diffusion coefficients predict overall survival in recurrent glioblastoma treated with bevacizumab. Neuro Oncol. 2011 Oct;13(10):1151-61.

Pope, W. B. et. al. Patterns of progression in patients with recurrent glioblastoma treated with bevacizumab. Neurology. 2011 Feb 1;76(5):432-7.

Radbruch, A. et. al. Relevance of T2 signal changes in the assessment of progression of glioblastoma according to the Response Assessment in Neurooncology criteria. Neuro Oncol. 2011 Dec 6.

Grabner, G. et. al. Longitudinal brain imaging of five malignant glioma patients treated with bevacizumab using susceptibility-weighted magnetic resonance imaging at 7 T. Magn Reson Imaging. 2012 Jan;30(1):139-47.

Price, S. J. et. al. Correlation of MR relative cerebral blood volume measurements with cellular density and proliferation in high-grade gliomas: an image-guided biopsy study. Am J Neuroradiol. 2011 Mar;32(3):501-6.

Löbel, U. et. al. Quantitative diffusion-weighted and dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging analysis of T2 hypointense lesion components in pediatric diffuse intrinsic pontine glioma. Am J Neuroradiol. 2011 Feb;32(2):315-22.

Wang, S. et. al. Differentiation between glioblastomas, solitary brain metastases, and primary cerebral lymphomas using diffusion tensor and dynamic susceptibility contrast-enhanced MR imaging. Am J Neuroradiol. 2011 Mar;32(3):507-14.